Sonnet BioTherapeutics (SONN) filed a registration statement with the US Securities and Exchange Commission Monday covering the potential sale of several securities from time to time.
The prospectus covers common stock and pre-funded warrants. Each pre-funded warrant will be exercisable for one share of common stock.
The company said it plans to use the net proceeds for research and development, including clinical trials, working capital, general corporate purposes, and to pay off debt.
Shares of Sonnet BioTherapeutics fell past 28% in recent tradind activity.
Price: 4.30, Change: -1.70, Percent Change: -28.33
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments